Outlook Therapeutics (OTLK) Eye Treatment Case

The defendant has requested the court to dismiss the case.

D. New Jersey

Court

2:23-cv-21862

Case number

12/29/2022

Class period Start

08/29/2023

Class period End

01/02/2024

Lead Plaintiff motion deadline

Outlook announced promising results for ONS-5010, suggesting FDA approval was near. However, they faced FDA setbacks and withdrew their application.
On August 30, 2023, the truth came out, leading to a 80% $OTLK fall.
Outlook Therapeutics announced positive data for ONS-5010 (its main product for wet AMD and retina diseases) in August 2021, suggesting it was ready for FDA approval, but then they withdrew and resubmitted their application due to FDA requests.

The lawsuit claims that throughout this time, Outlook provided false information about ONS-5010's effectiveness and manufacturing issues. 

As a result, the FDA recently rejected their application, causing $OTLK fall by 80% and $297M loss of market cap, damaging shareholders.

Given all the information, investors have reasons to suspect that Outlook's eye treatment faced manufacturing and FDA approval issues that weren't properly disclosed.

Case Status

Motion to dismiss

Alleged Offence

Mismanagement,

Misleading Statements,

Omissions

Suspected Party

Directors,

Management

Security Type

Stocks

Trade Direction

Long

Shock Event Date

08/30/2023

Filing date

11/03/2023

Lead Plaintiff Deadline

01/02/2024

Trusted by industry leaders

Endorsed by top professionals who trust our innovative solutions to drive impactful results.